Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acinar Cell Carcinoma Clear all
Completed Phase 1 Interventional

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

NCT00981162
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sorafenib tosylate, everolimus, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Aurora, Colorado • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Jun 25, 2026, 5:59 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

NCT06115499
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Nab paclitaxel, Gemcitabine, Cisplatin, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
345
States / cities
Anchorage, Alaska • Goodyear, Arizona • Phoenix, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer

NCT00004163
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
10
States / cities
New Haven, Connecticut • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer

NCT00851253
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Jun 25, 2026, 5:59 AM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

NCT02834013
View directory record Official record
Conditions
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1006
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 25, 2026, 5:59 AM EDT
Terminated Phase 1 Interventional

Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery

NCT01739439
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
gemcitabine hydrochloride, hyperfractionated radiation therapy, intensity-modulated radiation therapy, radiosurgery, diffusion-weighted magnetic resonance imaging
Drug · Radiation · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Jun 25, 2026, 5:59 AM EDT
Completed No phase listed Observational

Head & Neck Cancer Survivorship: Physical and Functional Status

NCT00751816
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
systemic chemotherapy, survey administration, adjuvant therapy, management of therapy complications, musculoskeletal complications management/prevention, physical therapy, radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT01839981
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
6,8-bis(benzylthio)octanoic acid
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

NCT00085371
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
triapine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Jun 25, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

NCT04858334
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
451
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 304 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 25, 2026, 5:59 AM EDT
Withdrawn Phase 1 Interventional

Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung

NCT01741597
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Recurrent Pancreatic Cancer, Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Interventions
dynamic contrast-enhanced magnetic resonance imaging, pharmacological study, tumor-homing peptide iRGD
Procedure · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Jun 25, 2026, 5:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Metastatic Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Acinar Cell Carcinoma
Interventions
ART0380, Gemcitabine, Irinotecan
Drug
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 25, 2026, 5:59 AM EDT
Terminated Early Phase 1 Interventional

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

NCT00499733
View directory record Official record
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Jun 25, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Results available

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

NCT05286827
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma
Interventions
Olaparib, ECG, CT CAP, Tumor Biopsy
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

NCT01156142
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
Interventions
doxepin hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
120
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Jun 25, 2026, 5:59 AM EDT
Active, not recruiting Not applicable Interventional

WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer

NCT02757859
View directory record Official record
Conditions
Acinar Cell Carcinoma, Ampulla of Vater Adenocarcinoma, Cholangiocarcinoma, Duodenal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm, Periampullary Adenocarcinoma
Interventions
Pancreatectomy, Lavage
Procedure · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
845 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Early Phase 1 Interventional

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

NCT01821612
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

NCT00031694
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
paclitaxel, bryostatin 1
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

NCT01537107
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose F 18
Drug · Procedure · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

NCT01658943
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
Interventions
Akt Inhibitor MK2206, Fluorouracil, Oxaliplatin, Selumetinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
534
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 350 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Jun 25, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Results available

Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer

NCT00416793
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
Interventions
bortezomib, carboplatin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Jun 25, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional

Title XELOX FOR SALIVARY GLAND CANCERS

NCT00101075
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Capecitabine, Oxaliplatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jun 25, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

NCT01234935
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method
Drug · Other · Genetic
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
17
States / cities
Alhambra, California • Fullerton, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Jun 25, 2026, 5:59 AM EDT